China Pharma (CPHI) vs IGC Pharma (IGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IGC Pharma (IGC) has outperformed China Pharma (CPHI) over the past year, losing 47.5% versus a loss of 72.6%. Over five years, IGC leads with a -87.6% price change compared with -99.8% for CPHI. IGC Pharma is the larger company by market cap ($19.6 million vs $18.9 million), about 1.0 times the size.
China Pharma converts more of its revenue into profit, with a net margin of -76.9% versus -560.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | IGC |
|---|---|---|
| Share price | $0.4384 | $0.168 |
| Market cap | $18.86M | $19.60M |
| 1-day change | -13.00% | -8.70% |
| YTD return | -63.77% | -40.00% |
| 1-year return | -72.60% | -47.50% |
| 5-year return | -99.84% | -87.65% |
| EPS (TTM) | $-0.42 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.14M | $1.27M |
| Revenue growth (YoY) | -8.49% | -5.50% |
| Net income (latest FY) | $-3.19M | $-7.12M |
| Gross margin | -3.18% | 48.70% |
| Operating margin | -78.16% | -585.84% |
| Net margin | -76.91% | -560.35% |
| 52-week high | $19.19 | $0.36 |
| 52-week low | $0.38 | $0.08 |
| Distance from 52-week high | -97.72% | -53.33% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +3471.43% |
| Average volume | 1.60M | 615.25K |
| Shares outstanding | 43.02M | 116.69M |
| Employees | 215 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IGC has outperformed CPHI by 25.1 percentage points over the past year.
- China Pharma is more profitable, keeping -76.9 cents of every revenue dollar as net income versus -560.3 cents for IGC Pharma.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
CPHI vs IGC FAQ
Which is bigger, China Pharma or IGC Pharma?
IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.86M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or IGC?
IGC returned -47.50% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and IGC Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.